Illumina (ILMN) is back in focus after the company and Nashville Biosciences expanded the Alliance for Genomic Discovery to 312,000 whole genomes and launched a 50,000 sample genome proteomics pairing initiative.

Illumina’s recent Alliance for Genomic Discovery expansion and multiomic push come as the share price sits at US$118.94, with a 1-day share price return of 2.92% but a year to date share price return decline of 11.47%. The 1-year total shareholder return of 38.95% contrasts with total shareholder return declines of 45.50% and 70.57% over three and five years. This suggests that recent momentum has picked up against a weaker long-term backdrop and that investors may be reassessing growth prospects and risks as new partnerships and datasets are announced.

If this kind of genomics news has your watchlist growing, it could be a good moment to scan our 33 healthcare AI stocks for more potential opportunities in the space.

With Illumina trading at US$118.94 and screens flagging a possible discount to some valuation measures, the real question is whether current prices still leave room for upside or if the market is already factoring in future growth.

Most Popular Narrative: 12.5% Undervalued

At a last close of $118.94 versus a widely followed fair value estimate of $135.94, Illumina’s story hinges on how durable its genomics demand and execution really are.

Strong and resilient growth in clinical applications, especially oncology, genetic disease testing, and reproductive health, continues to expand as genomic technologies become the standard of care, supporting both recurring revenues from consumables and long-term earnings visibility. Increasing adoption of next-generation sequencing for preventive healthcare and early disease detection is driving broader utilization of Illumina's platforms, particularly as clinical markets now represent over 60% of sequencing consumables, positioning the business for sustained volume and revenue growth.

Want to see what is baked into that fair value gap? The narrative leans on steady revenue expansion, shifting profit margins and a future earnings multiple that differs from today. Curious how those moving parts combine into one target number?

The most followed narrative uses a discount rate of 7.99%, ties fair value to expectations for mid single digit revenue growth and assumes profits settle at a lower margin level than today but still stay firmly positive. It also builds in a future P/E multiple that is higher than the current level yet still below the wider US Life Sciences group, and layers in expectations that the share count trends down over time.

The same narrative flags clear tensions, especially around China access and funding for research customers, and sets out what would need to hold for the numbers to stack up. It highlights that some analysts see room for upside into 2026 while others remain cautious, leading to a wide spread between the most optimistic and most conservative targets.

For you as an investor, the key question is whether those assumptions on growth, profitability and valuation multiples feel reasonable given Illumina’s exposure to clinical genomics, reimbursement frameworks and competitive pressures in sequencing. If they do, the gap between $118.94 and $135.94 may look like room the market has not closed yet. If not, the current price could already be closer to your own idea of fair value.

Result: Fair Value of $135.94 (UNDERVALUED)

However, that potential gap can close quickly if China access tightens again or if research funding and capital spending stay weaker than analysts currently assume.

Next Steps

With mixed sentiment running through this story, it helps to move quickly, review the underlying data yourself and weigh up 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Illumina has you thinking more broadly about your portfolio, now is the time to widen your search and see what else the market is offering.

• Target quality first by scanning companies with resilient financials and low leverage through our solid balance sheet and fundamentals stocks screener (42 results), so you are not relying on hope alone.
• Hunt for mispriced opportunities with our 48 high quality undervalued stocks, where strong business fundamentals meet prices that screens suggest may lag behind underlying quality.
• Build a watchlist of income ideas using the 14 dividend fortresses, focusing on companies offering 5%+ yields that screens highlight as potential dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.